MedPath

Effect of Led Therapy (630 ± 20nm) in Herpes Simplex Labial

Not Applicable
Conditions
Herpes simplex
herpes labialis
C02.256.466.382
C02.256.466.382.316
Registration Number
RBR-56f4w8
Lead Sponsor
niversidade do Vale do Paraiba UNIVAP
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruitment completed
Sex
Not specified
Target Recruitment
Not specified
Inclusion Criteria

age between 18 and 59 years old, Caucasian, first manifestation of the disease, history of cold sores and / or presented the lesion, healthy individual without comorbidities, agree and sign the Informed Consent Form, after clarifying the research.

Exclusion Criteria

presence of neoplastic lesions in the oral environment; HSV-2 lesion in the genitalia; belonging to the Fitzpatrick V and VI classification scale; pregnant or lactating women; hypersensitivity to any component in the acyclovir formula; liver or kidney problems against acyclovir indication ; intraoral herpes; For ethical reasons excluded volunteers received conventional treatment guidance.

Study & Design

Study Type
Intervention
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Primary outcome 1: Reduce disease onset time, number of recurrences, size of lesions, in the control period of five months after treatment. Checking by means of the patient's evaluation method with visual analog scale EVA, signs and symptoms lesion evaluation form and photographic control. From the observation of a variation of at least 5% in the pre and post-intervention measurements.;Expected outcome 1: Groups treated with low-level laser therapy have a higher performance compared to groups treated with conventional medication and control.
Secondary Outcome Measures
NameTimeMethod
Outcome found 1: Groups treated with conventional medication and control, presented slower repair times, recurrences in the control period, lesion size without decrease when recurrent. Groups treated with low-level laser therapy showed faster repair time and did not experience recurrences in the control period, five months.
© Copyright 2025. All Rights Reserved by MedPath